Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists by Flaig, Stephanie M. et al.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE / JUL-SEP 2016 / VOL 4 | ISSUE 3118
INTRODUCTION
Autosomal dominant polycystic kidney 
disease (ADPKD) is a genetic disorder 
characterized by the growth of  fluid-filled 
cysts predominately in kidney tubules and 
liver bile ducts. ADPKD has an estimated 
incidence of  1:400 to 1:1000, making it one 
of  the most common genetic diseases [1–3]. 
ADPKD progresses slowly and the fluid-
filled cysts grow in size due to increased 
rates of  epithelial cell proliferation together 
with increased fluid and electrolyte secretion 
into the cyst lumen. The expanding cysts 
compromise the normal kidney function 
and result in a decrease of  renal function 
to the point of  end-stage renal failure in 
midlife in approximately 50% of  patients[1, 4]. 
In the US, therapy is limited to cyst 
aspiration, dialysis, and eventually, renal 
transplantation after organ failure. Clinical 
trials for a variety of  agents have failed to 
produce an FDA-approved drug due to side 
effects that preclude life-long therapy.
* deceased
Address for Correspondence: 
Dr. Bonnie L. Blazer-Yost, Professor of 
Biology, Biology Department, SL358, 723 
West Michigan Street, Indianapolis, IN 
46202, USA.
Email: bblazer@iupui.edu
Access this article online
Website:  
www.intern-med.com
DOI:  
10.1515/jtim-2016-0028
Quick Response Code:
Original Article
ABSTRACT
Background and Objectives: The studies were designed to test the efficacy of two peroxisome 
proliferator-activated receptor γ (PPARγ) agonists in two rodent models of polycystic kidney 
disease (PKD). Materials and Methods: The PCK rat is a slowly progressing cystic model 
while the Wpk-/- rat is a rapidly progressing model. PCK rats were fed with a pharmacological 
(0.4 mg/kg body weight [BW]) and a sub-pharmacological (0.04 mg/kg BW) dose of rosiglitazone 
(week 4–28). Wpk-/- rats were fed with pharmacological (2.0 mg/kg BW) and sub-pharmacologic 
(0.2 mg/kg BW) doses of pioglitazone from day 5 to 18. At termination, kidney weights of treated 
versus untreated cystic animals were used to determine efficacy. The current studies were also 
compared with previous studies containing higher doses of PPARγ agonists. The concentrations 
used in the animals were calculated with reference to equivalent human doses for both drugs. 
Results: The current studies demonstrate: 1) that low, pharmacologically relevant, doses of the 
PPARγ agonists effectively inhibit cyst growth; 2) there is a class action of the drugs with both 
commercially available PPARγ agonists, rosiglitazone, and pioglitazone, inhibiting cyst growth; 
3) the drugs showed efficacy in two different preclinical cystic models. In the PCK rat, animals 
fed with a sub-pharmacological dose of rosiglitazone for 24 weeks had significantly lower 
kidney weights than untreated animals (3.68 ± 0.13 g vs. 4.17 ± 0. 11 g, respectively, P < 0.01) 
while treatment with a pharmacologic dose had no significant effect on kidney weight. The 
rapidly progressing Wpk-/- rats were fed with pharmacological and sub-pharmacologic doses of 
pioglitazone from day 5 to 18 and the kidneys were compared with non-treated, cystic animals. 
Kidney weights on the pharmacologic dose were not statistically lower than the untreated animals 
while rats fed a sub-pharmacologic dose showed a significant decrease compared with untreated 
animals (3.35 ± 0.15 g vs. 4.55 ± 0.46 g, respectively, P = 0.045). Conclusion: Concentrations of 
PPARγ agonists below the human equivalent diabetic doses are effective in slowing cyst growth 
in two rodent models of PKD.
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In 85% of  ADPKD patients, the genetic mutation occurs 
on chromosome 16, at the PKD1 gene locus that encodes 
the protein polycystin 1 (PC1). The other 15% of  genetic 
mutations occur on chromosome 4, at the PKD2 gene 
locus, encoding the protein polycystin 2 (PC2)[5]. Polycystins 
1 and 2 are found in the primary cilia, endoplasmic 
reticulum, junctional complexes, and the plasma membrane. 
In the primary cilia, the PCs form a complex that functions 
as a mechanosensitive Ca2+ channel with the characteristics 
of  a transient receptor potential (TRP) channel[6–8]. While 
PC2 is regarded as the TRP channel, mutations in either 
PC1 or PC2 cause remarkably similar disease progression. 
Loss of  function of  either PC1 or PC2 results in a decreased 
influx of  Ca2+. In the renal epithelial cells of  the distal 
nephron and cortical collecting duct, Ca2+ influx inhibits 
adenylyl cyclase VI and activates the Ca2+-stimulated 
phosphodiesterase 1. The decreased intracellular Ca2+ in 
ADPKD, therefore, leads to an increase in intracellular 
cAMP, a finding widely documented in cystic renal epithelia 
derived from preclinical cystic models and ADPKD 
patients. In the short term, the subsequent increase in 
protein kinase A (PKA) alters ion secretion, predominately 
via the cystic fibrosis transmembrane conductance regulator 
(CFTR). In the long term, an increase in intracellular cAMP 
stimulates increased cellular proliferation[2, 3].
Peroxisome proliferator activator receptor gamma (PPARγ) 
agonists are insulin-sensitizing agents used in the treatment 
of  type 2 diabetes mellitus[9–11]. PPARγ is expressed in the 
renal collecting duct [12]. Studies in cell culture models of  
the principal cell type of  the distal nephron have shown the 
PPARγ agonists inhibit cAMP-stimulated anion transport 
by inhibiting the synthesis of  the CFTR protein[13]. The 
dose response relationships for PPARγ agonist inhibition 
of  ADH-stimulated Cl- secretion via CFTR are an order of  
magnitude lower than the receptor transactivation profiles 
that characterize the drug’s effects on insulin sensitivity. 
Thus, it is reasonable to hypothesize that PPARγ agonists 
could be used as treatment for polycystic kidney disease 
(PKD). Previously, we [5] and others [14] have shown that a 
relatively high dose of  the PPARγ agonist, pioglitazone, was 
effective in decreasing the renal cystic burden in the PCK 
rat model. However, high doses of  PPARγ agonists have 
documented side effects, including edema and weight gain, 
leading to the suggestion that this class of  drug may not be 
ideal for life-long treatment of  a slowly progressing disease.
The current studies were designed to further test the class 
action effectiveness of  PPARγ agonists by examining 
another clinically used agonist, rosiglitazone, in the PCK rat 
model. In addition, to further explore the potential clinical 
relevance of  these compounds, preclinical testing was 
completed using doses equivalent to sub-pharmacological 
concentrations of  PPARγ agonists in the PCK rat as well 
as in a genetically distinct, rapidly progressing cystic model, 
the Wpk-/- rat.
MATERIALS AND METHODS 
Animals
PCK rats were purchased from Charles River Laboratories, 
Inc. (Wilmington, MA, USA). Heterozygous Wistar 
Wpk+/- rats were provided by Dr. Nauta (Erasmus Medical 
Center Rotterdam, Rotterdam, Netherlands). The breeding 
colonies were established, pathogen-free, and maintained at 
Indiana University School of  Medicine (IUSM) Laboratory 
Animal Resource Center. All animal studies were performed 
with approval of  the IUSM IACUC and adhered to the 
NIH Guide for the Care and Use of  Laboratory Animals. 
The animal protocols were designed to minimize pain or 
discomfort to the animals.
Methods
Both rosiglitazone (Avandia®) and pioglitazone (Actos®) 
were purchased in tablet form. PCK rats were fed 
rosiglitazone as part of  their chow starting at weaning 
(4 weeks of  age). Treatment groups were fed Purina 
no. 5002 LabDiet (control diet) supplemented with 
rosiglitazone calculated to provide the stated doses. Wpk-/- 
rats with cystic disease do not survive past weaning and, 
therefore, the pioglitazone was dissolved in grape juice to 
make it palatable for the suckling animals. Litters from 
heterozygous crosses were treated orally once daily from 
day 5 until day 18. The treated animals received either 
2.0 mg/kg body weight (BW) or 0.2 mg/kg BW based on 
each animal’s daily weight. 
On the day of  sacrifice, the animals were anesthetized with 
100 mg/kg intraperitoneally injected sodium pentobarbital. 
Blood was collected via intracardiac puncture and analyzed 
at IU Health Pathology Laboratory for serum electrolytes, 
glucose, and liver enzymes. Body weights were measured 
and the left kidney and right liver lobe were collected and 
frozen via liquid nitrogen. The body was flushed with saline 
and infused with 4% paraformaldehyde. The remaining 
kidney, liver, and heart were removed and stored in 4% 
paraformaldehyde. For histological analyses, the kidneys 
were embedded in paraffin. The paraffin samples were 
transversely sectioned (4 mmol/L sections) and stained 
with hematoxylin and eosin.
Statistical analysis
All statistical analyses were performed using SigmaPlot 
(version 12.5, Systat Software Inc.). In all comparisons, 
each group of  treated animals was compared with the 
control (untreated) group. Normality of  data distribution 
was tested using the F-test for unequal variance. Normally 
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distributed data were analyzed using Student’s t-test for 
unpaired samples. For data that were heteroscedastic, a 
Mann–Whitney U statistical text was used. In all cases, data 
were expressed as average ± standard error of  the mean 
(SEM) and were considered significant at the P ≤ 0.05 level.
RESULTS
Human equivalent doses used in animal feeding 
studies
Rodent studies examining the mechanism of  action of  
PPARγ agonists in normal animals have used supra-
pharmacologic levels of  the drugs [15–17]. The current studies 
have used more relevant concentrations that are analogous 
to those that would be used in humans. Table 1 provides 
the human equivalent doses (HED) of  the PPARγ agonists 
based on FDA-recommended conversion metrics [18].
Effect of rosiglitazone in the PCK rat model of 
renal cystic disease
To test the effects of  rosiglitazone, PCK rats were chosen 
to facilitate comparison with previous studies using 
pioglitazone. The PCK rat is orthologous to human 
autosomal recessive PKD, but is phenotypically more 
similar to human ADPKD. Like humans, the rats show 
a slowly progressing disease with gender dimorphism[19]. 
Females tend to develop less severe kidney disease and 
more severe liver disease.
PCK rats were treated with three doses of  rosiglitazone, 
a supra-pharmacological dose of  4 mg/kg BW (HED = 
45 mg/day), a pharmacological dose of  0.4 mg/kg BW 
(HED = 4.5 mg/day) or a sub-pharmacological dose of  0.04 
mg/kg BW (HED = 0.45 mg/day). For comparison, human 
diabetic patients are typically treated with 4 or 8 mg/day.
Eight animals were randomly assigned to each treatment 
group with 11 rats serving as control. Only female animals 
were used because of  gender dimorphism and to facilitate 
comparison with previously published data. The rats were 
fed either a control diet or a rosiglitazone-supplemented 
diet beginning at weaning and continuing for 24 weeks. In 
the cohort that received the high dose of  rosiglitazone, five 
animals had to be sacrificed early due to the development 
of  cholangitis, an infection of  the common bile duct. Due 
to the small number of  animals remaining, the fact that they 
were being administered an unrealistically high HED, and 
the finding that these remaining animals had an increase in 
BW (378.5  ± 2.47 g as compared to an average of  340.68 
± 5.5 g in animals on control diet), the decision was made 
not to include these animals in the summarized data. 
Figure 1 illustrates representative transverse sections of  the 
control and treated animals. Two sections from different 
animals were selected to show the high and low extremes of  
cystic burden. Interestingly, the pharmacologic dose did not 
substantially alter the number or size of  renal cysts while 
the treatment with the sub-pharmacologic dose significantly 
decreased cyst size and apparent number.
The administration of  either 0.4 or 0.04mg/kg BW 
rosiglitazone had no effect on BW, heart weight, or liver 
weight (Figure 2). No changes were observed in the 
hematocrits or serum and urine electrolytes (data not 
shown). The cystic burden, when measured as either total 
kidney weight or as kidney weight as a percentage of  BW, 
was statistically decreased only by the lowest concentration 
of  rosiglitazone (HED = 0.45 mg/day) (Figure 3). These 
data form a quantitative measure for the renal sections 
shown in Figure 1. While only the lowest concentration 
of  rosiglitazone decreases the kidney weight, both the 
pharmacological and sub-pharmacological doses were 
effective in reducing serum creatinine. The PCK rats have 
a relatively normal rodent glucose concentration and this 
was moderately decreased by 0.4 mg/kg BW treatment, 
but not by the sub-pharmacologic dose.
Effect of pioglitazone in the Wpk rat model of 
renal cystic disease
To examine the effectiveness of  PPARγ agonists in a 
genetically distinct model, the Wpk rats were used. Wpk 
rats have a mutation in TMEM67 and are an orthologous 
model for Meckel Gruber Syndrome type 3. The 
homozygous affected (Wpk-/-) animals exhibit rapidly 
progressing cystic disease and severe hydrocephalus while 
the heterozygous (Wpk+/-) rats have no renal phenotype 
and live to adulthood[19–21]. The homozygous affected 
animals do not survive past three weeks of  age. Wpk-/- rats 
were treated with pharmacologic (2.0 mg/kg BW; HED 
22.7 mg/day) and sub-pharmacological (0.2 mg/kg BW) 
doses of  pioglitazone from postnatal day 5 to 18.
As in the PCK rats, pioglitazone did not cause increases 
in BW (Figure 4), liver weight, liver weight as a percentage 
BW or hematocrits (data not shown). The heart weight was 
statistically lower in the animals treated with the low dose. 
In the Wpk-/- rat model, the glucose levels in the untreated 
animals were above the normal values for rodents. The 
HED of  22.7 mg/day pioglitazone returned these levels 
to more normal values while the sub-pharmacological dose 
of  0.2 mg/kg BW (HED = 2.27mg), trended lower, but 
did not reach statistical significance (P = 0.067; 2-tailed 
Student’s t-test).
With regard to the effectiveness of  the PPARγ agonist on 
cystic burden in Wpk rat model, only the administration 
of  the pioglitazone at the sub-pharmacologic dose was 
shown to be effective in statistically decreasing renal kidney 
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weight (Figure 4). These data are consistent with the effect 
of  low-dose rosiglitazone in the PCK rat model.
DISCUSSION
ADPKD is often first diagnosed in young adults who 
experience flank pain due to the growth of  multiple renal 
cysts. The cyst expansion is unrelenting and, in many 
patients, progresses to renal failure in midlife. In the U.S., the 
only approved therapies for this disease are cyst aspiration 
for pain management and dialysis or renal transplantation 
when the kidneys fail. Thus, there is a critical need for safe, 
inexpensive treatments that can delay the progression of  
cyst enlargement and the accompanying destruction of  
the renal parenchyma that can lead to renal failure. Several 
drugs, such as the V2 receptor agonist tolvaptan as well as 
immunosuppressive and chemotherapeutic agents, have 
entered or, in the case of  tolvaptan, completed clinical 
trials[22–24]. However, these drugs have side effects that may 
limit patient compliance as well as safety of  long-term use. 
Our overall goal is to develop safe, efficacious drugs that 
can be used as life-long medications starting at the time of  
diagnosis in ADPKD patients. 
Renal cell culture studies showed that the PPARγ agonists’ 
inhibitory effect on CFTR, the ion channel responsible for 
cyst growth, occurs at a concentration that is approximately 
10-fold lower than the EC50s for receptor transactivation and 
that PPARγ agonists decrease CFTR synthesis [13]. In vivo, in 
the bile duct, PPARγ agonists decrease the amount of  CFTR 
on the apical membrane[5]. The decrease in CFTR channels or 
channel activity can be measured using electrophysiological 
techniques, but the low abundance in the kidney precludes 
the quantification of  the apical channels localized in the 
principal cells. However, we postulate that the mechanism 
is likely the same in both the renal tubule and the bile duct, 
namely, a decrease in apical expression of  CFTR.
Previous studies have examined the effectiveness of  PPARγ 
agonists on PKD in rodent models. In the embryonic 
lethal PKD1 knockout mouse, homozygous embryos 
have hydrops, cardiac conotruncal defects, and renal 
cystogenesis[25]. Maternally administrated pioglitazone 
(80 mg/kg/day) improved the survival of  the embryos by 
several days, with a decrease in renal cystogenesis, via an 
unknown mechanism[25]. A separate PC-PKD1-KO model 
presents as a rapidly progressing, but less severe phenotype 
Figure 1: Histological kidney sections from naïve and rosiglitazone-treated PCK rats. The images show transverse histological sections of kidneys from the PCK rats after 
24 weeks of feeding beginning in the post-weaning period. Sections taken from animals treated with a diet containing 0.4 mg/kg BW (HED = 4.5 mg/day) or 0.04 mg/
kg BW (HED = 0.45 mg/day) are compared to littermates fed a control (normal chow) diet. The two sections are taken from kidneys of different animals and illustrate 
the extremes of cystic burden in each of the groups.
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Figure 2: Effect of long-term rosiglitazone treatment on body weight, heart weight, and liver cyst burden in the PCK rat. Animals were fed rosiglitazone at the concentrations 
listed starting at the time of weaning (4 weeks) for 24 weeks. Data are plotted as means  ± SEM with the number of animals in each cohort listed at the base of the 
column. None of the treatments resulted in a statistically significant change in the treated animals as compared to the rats on a control diet.
Figure 3: Effect of long-term rosiglitazone treatment on kidney cyst burden, serum creatinine, and serum glucose in the PCK rat. Animals were fed rosiglitazone at the 
concentrations listed starting at the time of weaning (4 weeks) for 24 weeks. Data are plotted as means  ± SEM with the number of animals in each cohort listed at the 
base of the column. * denotes mean values that were statistically lower than the control fed animals (P < 0.05) by the Student’s t-test.
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in which the mice develop cystic disease at approximately 
1 month of  age and survive for 2 months. The dams were 
treated with 30 mg/kg food weight (estimated to be 4.8 mg/
kg BW/day) pioglitazone and the same concentration was 
continued after weaning. This dose did not decrease cyst 
burden or change renal function, but did decrease blood 
pressure and increase survival[26]. In a slow-progressing 
model, the Han:SPRD rat, which demonstrates proximal 
cystic disease, rosiglitazone at 10 mg/kg BW/day decreased 
the renal cystic burden, protected renal function, and 
prolonged survival in short-term (8 weeks post weaning) 
and long-term (6 months post weaning) studies [27].
The PCK rat model is a slowly progressing model that 
has been used extensively for preclinical testing [28, 29]. In a 
previous study, the PCK rat was treated with pioglitazone 
for either 7 or 14 weeks directly after weaning [5] (Table 1). 
The results showed an improvement in renal and liver cyst 
burden accompanied by a decrease in apical expression 
of  CFTR in bile duct epithelia[5]. The current studies were 
designed to extend these findings into pharmacologically 
relevant doses in an alternative model and to determine 
the class action of  the PPARγ agonists on the cyst growth 
in the PCK rat model.
In PCK rats, an extended treatment of  24 weeks with 
rosiglitazone reduced renal cystic burden. However, the 
highest dose, 4.0 mg/kg BW, resulted in the development 
of  cholangitis in the majority of  the animals. This dose of  
rosiglitazone was chosen to match the previous pioglitazone 
study, which was conducted for 7 or 14 weeks[5]. In the 
pioglitazone study, no animals developed cholangitis and it 
is unknown whether the pioglitazone would have the same 
effect if  the studies were of  a similar duration. The etiology 
of  the cholangitis is unknown, but is likely related to the 
higher dose treatment since none of  the control or lower 
dose-treated animals developed this problem. The animals 
on 4.0 mg/kg BW also showed statistically significant 
weight gain, likely from the propensity of  rosiglitazone 
to cause fluid retention. Regardless, this concentration 
of  the PPARγ agonist is unrealistically high and the data 
regarding the remaining three rats on the highest dose are 
not included.
At the pharmacological (0.4 mg/kg BW) or sub-
pharmacological (0.04 mg/kg BW) rosiglitazone doses, the 
known side effect of  fluid retention does not appear to be 
relevant. There were no statistical changes in hematocrits 
(data not shown), total BW, or heart weight. As an insulin-
Figure 4: Effect of short-term pioglitazone treatment in the Wpk-/- rat. Animals were fed pioglitazone at the concentrations listed starting at postnatal day 5 and continuing 
until postnatal day 18. Data are plotted as means  ± SEM with the number of animals in each cohort listed at the base of the column. * denotes mean values that were 
statistically lower than the control fed animals (P < 0.05) by the Student’s t-test.
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sensitizing agent, the rosiglitazone lowered the serum 
glucose only when administered at a pharmacological level 
of  0.4 mg/kg BW. Neither dose was effective in mitigating 
the liver cyst burden. Renal cyst burden as assessed by total 
kidney weight or by kidney weight as a percentage of  BW 
was diminished by only the lowest dose of  rosiglitazone 
(HED = 0.45 mg/day). In contrast, serum creatinine was 
statistically lower after treatment with either 0.4 or 0.04 
mg/kg BW indicating a beneficial effect on renal function 
that measurement of  kidney weight is likely not sensitive 
enough to detect. These data together with previously 
published studies using pioglitazone[5], indicate that the 
effects of  PPARγ agonists on the reduction of  cyst burden 
in the PCK rat is a class action effect. In agreement with 
the tissue culture studies, the current studies show that the 
effect is manifested at sub-pharmacological doses. 
The Wpk rat model was used to extend the studies to 
an additional, unrelated, preclinical model. This is a 
rapidly progressing model in which the kidneys represent 
approximately 15% of  the BW by day 18. The Wpk-/- rats 
were treated with pioglitazone from postnatal day 5 to 
18. The two treatment doses represent a pharmacologic 
dose compared to a sub-pharmacologic dose. The 
pharmacologic dose was not effective in reducing the 
cystic burden in the short-term treatment necessitated by 
the rapidly progressing Wpk model.
For unknown reasons, the blood glucose in the Wpk-/- 
rats was unusually high. The increased blood glucose 
was significantly decreased by pharmacological levels of  
pioglitazone, but was not significantly decreased by the 
lower dose. The average heart weight was significantly 
decreased by the low-dose treatment, but this significance 
was lost when expressed as a percentage of  BW (data not 
shown). Likewise, the hematocrits were unaffected by the 
drug treatment, indicating that the PPARγ agonist-induced 
fluid retention is not seen at either concentration.
Total kidney weight was significantly decreased only in 
the low-dose treated animals. This is remarkably similar 
to results obtained in response to sub-pharmacological 
treatment with rosiglitazone in the PCK rats.
In conclusion, the efficacy of  PPARγ agonist concentrations 
acting as insulin sensitizing agents by reducing elevated 
serum glucose, is in agreement with previous rodent 
and human studies. Interestingly, there is consistency 
in the current studies that sub-pharmacologic levels of  
both pioglitazone and rosiglitazone are more effective in 
reducing cyst burden in the rodent models than higher 
concentrations. The reported side effects of  the PPARγ 
agonists are dose-related and, therefore, it is expected that 
minimal adverse effects will be associated with low-dose 
treatment.
Presumably, most of  the agents in clinical and preclinical 
trials target ADPKD treatment beginning at the time 
of  diagnosis with the rationale that the earlier the 
intervention to slow cyst proliferation and expansion, the 
better the prognosis. The development of  pharmaceutical 
interventions to be initiated at the time of  diagnosis, 
typically in young adulthood or earlier, imposes several 
considerations. Most importantly, the side-effect profile 
Table 1: Summary of drug treatment comparing rat and human doses
                                      Pioglitazone
Animal model Drug treatment duration Dose in rats 
mg/kg BW
Equivalent human dose 
mg/day
% decrease  
in KW/BW *
PCK rat - females 14 weeks (weeks 4–18) 20 227 20.7
PCK rat - males 7 weeks (weeks 3–10) 20 227 15.8
PCK rat - females 7 weeks (week 3–10) 4 45 28.7
PCK rat - males 7 weeks (week 3–10) 4 45 26.3
Wpk-/- rats Day 5–18 2.0 22.7 −7.6
Wpk-/- rats Day 5–18 0.2 2.27 16.6
Rosiglitazone
PCK rat (females) 24 weeks (week 4-28) 0.4 4.5 −4.1
PCK rat (females) 24 weeks (week 4-28) 0.04 0.45 10.6
Notes: The equivalent human dose was calculated using the metric established by the FDA [18] and normalized to a 70 kg human. For comparison, standard 
dosing in humans for the treatment of diabetes is 15, 30, and 45 mg/day for pioglitazone and 4 or 8 mg/day for rosiglitazone. Where no gender is specified, 
both male and female animals were combined. Positive values denote a lower kidney mass as a percentage of body weight of treated animals when 
compared to untreated animals. The calculated values for the PCK rats treated with pioglitazone were taken from Blazer-Yost et al. [5] and the values for  
Wpk-/- rats treated with pioglitazone and for PCK rats treated with rosiglitazone were calculated from the data obtained in the current study.
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must be highly favorable. There is no benefit to treating a 
slowly progressing disease with drugs whose side effects 
are likely to cause cumulative damage to patients that is 
equal in severity to the disease progression. In addition, 
since patient compliance is of  utmost importance, it is 
crucial that a potential drug does not have an impact on 
the patient’s life-style, particularly in young, asymptomatic 
patients. The polyuria and potential for dehydration while 
using V2 receptor antagonists such as tolvaptan are of  
concern for patient compliance. Finally, the financial 
burden of  life-long drug treatment has to be considered 
for both the patient and the healthcare systems world-wide. 
PPARγ agonists represent a relatively low-cost alternative 
to more expensive drugs that are being developed for 
ADPKD treatment[30, 31].
CONCLUSION 
PPARγ agonists may be useful as life-long treatment for 
ADPKD.
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